Plasmablastic lymphoma in a human immunodeficiency virus negative patient

Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, Delhi - 110 085, India.
Indian Journal of Pathology and Microbiology (Impact Factor: 0.47). 04/2010; 53(2):368-9. DOI: 10.4103/0377-4929.64281
Source: PubMed
4 Reads
  • Source
    • "Only a small subset of reported cases have occurred in immunocompetent patients . (Delecluse et al. 1997; Nguyen et al. 2003; Colomo et al. 2004; Scheper et al. 2005; Takahashi et al. 2009; Thakral et al. 2009; Teruya-Feldstein et al. 2004; Kim et al. 2009; Cha et al. 2010; Kravetz et al. 2006; Masgala et al. 2007;Lin et al. 2004; Khurana & Jaipota 2010; Pruneri et al. 1998; Lee et al. 2006; Gogia & Bakhshi 2010; Lipstein et al. 2010; Mihaljevic et al. 2011; Guan et al. 2011; Brahmania et al. 2011; Mondal et al. 2011; Mansoor et al. 2012) Table 1. A standardized, optimal chemotherapeutic regime for PBL is yet undefined. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasmablastic lymphoma (PBL) is a rare and aggressive variant of diffuse large B cell lymphoma. The prognosis of PBL patients is poor. The majority of patients succumb to a fulminant disease course, with most dying in the first year after diagnosis. The small number of HIV-negative PBL cases reported in the literature to date is composed of single case reports and small case series. Consequently, the natural history of the disease in HIV-negative individuals and the optimum treatment are not well characterized. Intensive induction chemotherapy has been associated with marked improved overall survival. However the optimal regimen has not been defined. We describe the third case of PBL of the maxillary sinus which occurred in a 24-year old HIV-negative man. We outline the clinicopathological features and report success using a hyper-CVAD regimen with 6 cycles and consolidation radiation therapy yielding a complete remission of four years.
    SpringerPlus 12/2013; 2(1):142. DOI:10.1186/2193-1801-2-142
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasmablastic lymphoma (PBL) is an aggressive variant of non-Hodgkin lymphoma initially reported in the oral cavity of HIV-positive individuals. Since its original description, several cases have been reported in patients who do not have HIV infection. However, despite its recognition as a distinct subtype of diffuse large B-cell lymphoma several years ago, comprehensive reviews of this entity are lacking. A MEDLINE search through June 2010 was performed to identify cases with a pathologic diagnosis of HIV-negative PBL based on morphology and minimal immunohistochemical criteria. Our study included a total of 76 cases. The median age was 57 years (range, 1 to 90 years) with a male-to-female ratio of 1.7. Seventy-four percent of cases did not have an apparent association with immunosuppression, 18% had a concurrent lymphoproliferative or autoimmune disorder and 9% developed PBL after solid organ transplantation. Oral involvement was observed in 21%, advanced stage in 60%, Epstein-Barr virus-encoded RNA expression was positive in 45% and Ki-67 expression of greater than or equal to 80% in 61% of the cases. Chemotherapy was documented in 43 patients, from which 43% received the cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like regimens. The median and the 2-year overall survival for the whole group were 9 months and 10%, respectively. Patients who had HIV-negative PBL have distinct clinicopathological characteristics, such as short overall survival and lower rates of oral involvement and Epstein-Barr virus-encoded RNA expression than the previously reported in HIV-positive patients.
    Clinical lymphoma, myeloma & leukemia 04/2011; 11(2):185-9. DOI:10.1016/j.clml.2011.03.008 · 2.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Plasmablastic lymphoma (PBL) is a rare aggressive B-cell lymphoproliferative disorder. HIV-negative PBL has not been extensively reported. Nine HIV-negative PBL patients evaluated at Moffitt Cancer Center were studied. Eight patients had extranodal diseases. All patients were treated with CHOP or hyper-CVAD. Responses were observed in 8 cases (7 complete, 1 partial responses). Four patients underwent consolidation with autologous hematopoietic stem cell transplant (HSCT) in first complete remission (CR1). At median follow-up of 23.9 months, 7 patients were alive and 5 were disease-free. Aggressive induction chemotherapy and consolidation with autologous HSCT in CR1 might be considered for patients with HIV-negative PBL.
    Leukemia research 07/2011; 35(12):1571-7. DOI:10.1016/j.leukres.2011.06.023 · 2.35 Impact Factor
Show more